EGFR and neoplasm: Although patients with right-sided tumors consistently had worse prognoses than patients with left-sided tumors, they may still derive tumor shrinkage benefits with anti-EGFR-mAb-based treatment, according to a meta-analysis by Wang et al. (including the CRYSTAL, TAILOR, PRIME, and 20050181 trials) that demonstrated that anti-EGFR-mAb-based treatment significantly improves response rates and PFS in patients with RAS wt mCRC, independent of primary tumor location (97).